We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
DeadHappy is a digital-first life insurance provider that aims to disrupt the £3.7 billion life insurance market. The company claims that traditional life insurance is complex, expensive, and inflexible. DeadHappy argues that it can offer customers a cheap, flexible and enjoyable alternative. It has developed a unique pay-as-you-go life insurance product with a rolling 10 year guarantee of cover. A simple sign-up process allows customers to answer only 4 medical questions & obtain cover in under 5 minutes, on-line, via their mobile phone. The company's proprietary Deathwish Platform enables customers to personalise their life insurance by creating ‘Deathwishes’. In 2020, DeadHappy reached 120,000+ total deathwishes and has sold 7,800+ total life insurance policies. The company will use 35% of the investment for company growth, 30% for technology development, 20% for product development, and 15% to build partnerships.
days to go: Expired investment: £2,703,820
WiseAlpha is an investment platform that allow its members the opportunity to invest in secured loan investments from some leading UK companies.  
days to go: Expired investment: £579,150
Yielders is a real-estate investment platform that minimises the barriers of entering a traditionally inaccessible asset class. This award-winning platform is the UK’s first finance FinTech company which is regulated by FCA. The company had received authorization from FCA in 2017. Yielders received 2017 Islamic Economy Award and became finalist twice for the EFICA Innovative Finance award. It also received IFN's global award for the Best Islamic Crowdfunding Platform category. The company has over 2500 on-boarded investors. The company has achieved and completed more than £6m AUM. Yielders aims to deliver steady returns for a conscientious modern investor. Yielders plans to utilise the proceeds for product development, technology, talent acquisition, and building its presence around GCC, the UK and the global Islamic Market.
days to go: Expired investment: £686,178
A fully integrated, end to end platform that enables real time situation and work force management, for the private security industry.  It ensures regulatory compliance and real time reporting for security operatives.  FalconDHQ is addressing a gap in the market to modernise the current paper based process.        
days to go: Expired investment: £415,000
Investly are an invoice financing marketplace that help European businesses finance their invoices by bringing them the best price from multiple providers. In 2 years they have financed just over £18m worth of invoices.
days to go: Expired investment: £679,085
Clim8 is a financial technology company that aims to move billions of pounds of investment into sectors such as clean energy, clean technology, sustainable food, smart mobility, and recycling. It is authorised by the Financial Conduct Authority (FCA). The company quotes United Nations data arguing that the World needs to invest $2.4 trillion every year into clean energy, from now until 2035, to meet climate change targets. Clim8 aims to capitalise on this objective. It launched its app on iOS and Android in private beta in October 2020 and then in the App Store in March 2021. It claims that its users have invested from £25 up to £97,000. The company has raised £5 million in venture capital to date, secured up to £2 million in airtime for equity from Channel 4 Ventures, and garnered a 4.8 star rating in the App Store, from a cumulative 100 reviews. The company will use the investment to accelerate user acquisition and launch new product offerings including pensions.
days to go: Expired investment: £2,849,790
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph